Alnylam Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past. Alnylam Pharmaceuticals stock Target Raised by Morgan Stanley on 10/12/2021. In a note to investors, the firm issued a new target price of $242.00. The analysts previously had $234.00 target price. Morgan Stanley’s price target would indicate a potential upside of 18.32% from the stock’s previous close.
Shares of Alnylam Pharmaceuticals traded down -$0.32 on monday, reaching $204.21. 28475 shares of the stock traded hands, compared to its average volume of 538857. On monday, Shares of Alnylam Pharmaceuticals closed at $204.21. The firm’s 50 day moving average is $193.87 and its 200 day moving average is $162.37.Alnylam Pharmaceuticals has a 12 month low of $119.29 and a 12 month high of $209.73. While on yearly highs and lows, Alnylam Pharmaceuticals today has traded high as $206.51 and has touched $202.67 on the downward trend.
Alnylam Pharmaceuticals Earnings and What to expect:
Alnylam Pharmaceuticals last released its earnings data on August 2nd, 2021. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, meeting the consensus estimate of ($1.61). The company had revenue of $220.55 million for the quarter, compared to analysts’ expectations of $193.66 million. Its revenue was up 112.1% compared to the same quarter last year. Alnylam Pharmaceuticals has generated ($7.46) earnings per share over the last year (($7.59) diluted earnings per share). Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($6.15) to ($3.89) per share. Alnylam Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.
Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($6.15) to ($3.89) per share. The P/E ratio of Alnylam Pharmaceuticals is -26.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Alnylam Pharmaceuticals is -26.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Alnylam Pharmaceuticals has a P/B Ratio of 23.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Alnylam Pharmaceuticals (NASDAQ:ALNY) Moving Average Technical Analysis
5 day Moving Average is $$202.11 And 5 day price change is $9.51 (4.88%) with average volume for 5 day average is 358,620. While technical analysis for average 20 days shows significant difference, 20 day moving average is $190.78 and 20 day price change is $18.74 (10.09%) and average 20 day moving volume is 561,980. 50 day moving average is $193.87 and 50 day price change is $25.59 ( 14.30%) and with average volume for 50 days is : 606,212. 200 day moving average is $162.37 and 200 day price change is $65.91 (47.55%) and with average volume for 200 days is : 621,988.
Other owners latest trading in Alnylam Pharmaceuticals :
- On 10/8/2021 shares held by Veriti Management LLC were 2,100 which equates to market value of $0.40M and appx 0.10% owners of Alnylam Pharmaceuticals
- On 10/7/2021 shares held by Berman Capital Advisors LLC were 469 which equates to market value of $88K and appx 0.00% owners of Alnylam Pharmaceuticals
- On 9/17/2021 shares held by Virtu Financial LLC were 3,092 which equates to market value of $0.52M and appx 0.10% owners of Alnylam Pharmaceuticals
- In total Institutional ownership equates to Institutional Ownership Percentage: 93.34% for Alnylam Pharmaceuticals
See More Analyst Rating at: RATING